Increasing incidence of multidrug resistant Pseudomonas aeruginosa in inpatients of a tertiary care hospital

Prakash, Ved; Mishra, Prem Prakash; Premi, H. K.; Walia, Apoorva; Dhawan, Sanju; Kumar, Abhishek

doi:10.5455/2320-6012.ijrms20141111

Cited by 17 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shrestha et al [33] and Mishra et al [28] also reported around 96% and 95% MDR A. baumannii, respectively. We found 73.3% MDR P. aeruginosa isolates which are higher than those reported by Mishra et al [34] from Nepal in 2008 (65.9%), Prakash et al [35] from India in 2014 (31.7%), and Hassuna et al [36] from Egypt in 2015 (56%). The rate of MDR P. aeruginosa is in an upward trend throughout the world especially in developing countries causing a life-threatening situation.…”

Section: Discussioncontrasting

confidence: 66%

Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal

et al. 2020

View full text Add to dashboard Cite

Objective: This study was designed for the characterization and establishment of antibiotic susceptibility profiles of non-fermentative gram negative bacteria isolated from hospitalized patients in a tertiary care hospital of Nepal. Results: A total of 402 non-fermentative gram negative bacteria was isolated in 1486 culture-positive cases from 6216 different clinical samples obtained from hospitalized patients. Among total non-fermentative gram negative bacterial isolates, the highest number was recovered from specimens collected from lower respiratory tract infections (n = 173, 43.0%) of hospitalized patients followed by pus/swab samples (n = 99, 24.6%) and urinary tract infections (n = 49, 12.2%). The most common non-fermentative gram negative bacteria identified were Acinetobacter baumannii (n = 177, 44.0%), Pseudomonas aeruginosa (n = 161, 40.1%) and Burkholderia cepacia complex (n = 33, 8.2%). These bacterial isolates exhibited a higher rate of insusceptibility to beta-lactam antibiotics, fluoroquinolones, and aminoglycosides. On the other hand, all the isolates of P. aeruginosa and A. baumannii were completely susceptible to colistin sulfate and polymyxin B. Among total isolates, 78.1% (n = 314) were multidrug-resistant with a high rate of multidrugresistant among A. baumannii (91.0%).

show abstract

Section: Discussioncontrasting

confidence: 66%

Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal

et al. 2020

View full text Add to dashboard Cite

show abstract

“…6,16,17 The incidence of infections caused by MDRPA and KPMDR strains has increased patient morbidity and mortality in healthcare settings in Colombia and worldwide because they cause infections in hospitalized or immunocompromised individuals. 5,9,[16][17][18][19] Infections caused by these MDR bacteria are becoming more difficult to treat because of their limited susceptibility to antimicrobial agents, resulting in a growing problem regarding the selection of effective antibiotic treatments. 6,7 Therefore, the development of new antibiotics or alternative therapeutic strategies for the treatment of infections caused by MDR bacteria is urgently needed.…”

Section: Evolutionary Bioinformaticsmentioning

confidence: 99%

A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa

Ocampo-Ibáñez

Liscano

Sánchez

et al. 2020

Evol Bioinform Online

View full text Add to dashboard Cite

Infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa and Klebsiella pneumoniae are a serious worldwide public health concern due to the ineffectiveness of empirical antibiotic therapy. Therefore, research and the development of new antibiotic alternatives are urgently needed to control these bacteria. The use of cationic antimicrobial peptides (CAMPs) is a promising candidate alternative therapeutic strategy to antibiotics because they exhibit antibacterial activity against both antibiotic susceptible and MDR strains. In this study, we aimed to investigate the in vitro antibacterial effect of a short synthetic CAMP derived from the ΔM2 analog of Cec D-like (CAMP-CecD) against clinical isolates of K pneumoniae (n = 30) and P aeruginosa (n = 30), as well as its hemolytic activity. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of CAMP-CecD against wild-type and MDR strains were determined by the broth microdilution test. In addition, an in silico molecular dynamic simulation was performed to predict the interaction between CAMP-CecD and membrane models of K pneumoniae and P aeruginosa. The results revealed a bactericidal effect of CAMP-CecD against both wild-type and resistant strains, but MDR P aeruginosa showed higher susceptibility to this peptide with MIC values between 32 and >256 μg/mL. CAMP-CecD showed higher stability in the P aeruginosa membrane model compared with the K pneumoniae model due to the greater number of noncovalent interactions with phospholipid 1-Palmitoyl-2-oleyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (POPG). This may be related to the boosted effectiveness of the peptide against P aeruginosa clinical isolates. Given the antibacterial activity of CAMP-CecD against wild-type and MDR clinical isolates of P aeruginosa and K pneumoniae and its nonhemolytic effects on human erythrocytes, CAMP-CecD may be a promising alternative to conventional antibiotics.

show abstract

“… Please note that the table includes ONLY those antibiotics which are deleted or newly added since 2010 . = Antibiotics deleted from CLSI guidelines between 2010 and 2018; 1, New antibiotics added in the CLSI guidelines since 2010 ; = No resistance reported till date ; = Resistance reported; Ef, E. faecium; S, S. aureus; K, K. pneumoniae; A, A. baumannii; P, P. aeruginosa; E= Enterobacter spp . S = (Long et al, 2014; Chan et al, 2015; Nigo et al, 2017); K = (Zowawi et al, 2015; Vuotto et al, 2017; Stanley et al, 2018); A = (Göttig et al, 2014; Goic-Barisic et al, 2017; Nowak et al, 2017; Caio et al, 2018; Chuang and Ratnayake, 2018); P = (Prakash et al, 2014; Gill et al, 2016; Alipour et al, 2017; Mohapatra et al, 2018; Palavutitotai et al, 2018) ; E = (Lee et al, 2015; Babouee Flury et al, 2016; Zeng et al, 2016; Kulengowski et al, 2018) .…”

Section: Introductionmentioning

confidence: 99%

“…S = (Long et al, 2014; Chan et al, 2015; Nigo et al, 2017); K = (Zowawi et al, 2015; Vuotto et al, 2017; Stanley et al, 2018); A = (Göttig et al, 2014; Goic-Barisic et al, 2017; Nowak et al, 2017; Caio et al, 2018; Chuang and Ratnayake, 2018); P = (Prakash et al, 2014; Gill et al, 2016; Alipour et al, 2017; Mohapatra et al, 2018; Palavutitotai et al, 2018) ;…”

Section: Introductionmentioning

confidence: 99%

Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review

et al. 2019

View full text Add to dashboard Cite

The acronym ESKAPE includes six nosocomial pathogens that exhibit multidrug resistance and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp. Persistent use of antibiotics has provoked the emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) bacteria, which render even the most effective drugs ineffective. Extended spectrum β-lactamase (ESBL) and carbapenemase producing Gram negative bacteria have emerged as an important therapeutic challenge. Development of novel therapeutics to treat drug resistant infections, especially those caused by ESKAPE pathogens is the need of the hour. Alternative therapies such as use of antibiotics in combination or with adjuvants, bacteriophages, antimicrobial peptides, nanoparticles, and photodynamic light therapy are widely reported. Many reviews published till date describe these therapies with respect to the various agents used, their dosage details and mechanism of action against MDR pathogens but very few have focused specifically on ESKAPE. The objective of this review is to describe the alternative therapies reported to treat ESKAPE infections, their advantages and limitations, potential application in vivo , and status in clinical trials. The review further highlights the importance of a combinatorial approach, wherein two or more therapies are used in combination in order to overcome their individual limitations, additional studies on which are warranted, before translating them into clinical practice. These advances could possibly give an alternate solution or extend the lifetime of current antimicrobials.

show abstract

Increasing incidence of multidrug resistant Pseudomonas aeruginosa in inpatients of a tertiary care hospital

Cited by 17 publications

References 14 publications

Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal

Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal

A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa

Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review

Contact Info

Product

Resources

About